Latest News

Ceapro Announces New Collaboration and Funding Agreement Targeting Novel High Value Active Ingredients

EDMONTON, ALBERTA–(Marketwire – June 14, 2011) – Ceapro Inc. (TSX VENTURE:CZO) today announced that it has entered into a Material Transfer Agreement (MTA) with the National Research Council of Canada (NRC) to evaluate a new series of potentially high-value active ingredients from a variety of rosehips uniquely

Read more

Ceapro Announces Payout of Royalty Obligation

EDMONTON, ALBERTA, CANADA–(Marketwire – June 7, 2011) – Ceapro Inc. (TSX VENTURE:CZO) today announced that it is issuing cash payments totaling approximately $378,000 to its royalty holders which represents the full payment of this accrued obligation at December 31, 2010, Ceapro’s last publically reported quarter. “Since 2008

Read more

Ceapro Reports Full-Year 2010 Financial and Operating Results

EDMONTON, ALBERTA–(Marketwire – April 20, 2011) – Ceapro Inc. (TSX VENTURE:CZO) (“Ceapro” or “the Company”) today released financial and operating results for the fiscal year ended December 31, 2010. FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2010 Total sales of $5,577,000 compared to $4,370,000 in 2009,

Read more

Ceapro Announces Additional Key Patents Granted in Europe, Japan and United States of America

EDMONTON, ALBERTA–(Marketwire – April 19, 2011) – Ceapro Inc. (TSX VENTURE:CZO) (“Ceapro” or the Company”) is pleased to announce that patent offices in Europe, Japan and USA have issued the following patents to protect Ceapro’s inventions: One of our core products, Avenanthramides: the office of the USA patents has

Read more

Ceapro Announces Debt Reduction

EDMONTON, ALBERTA–(Marketwire – Jan. 10, 2011) – Ceapro Inc. (TSX VENTURE:CZO) today announced that pursuant to a debt settlement agreement made with the members of its board of directors previously announced on December 13, 2010, it has issued 1,590,909 common shares in full satisfaction of debts totaling

Read more
Page 10 of 10« First...678910